Become a Mindbloom Affiliate

Learn about Mindbloom’s affiliate program and evidence based treatment model for treating anxiety and depression.

Apply now
Apply to Mindbloom’s affiliate
program in Impact.

What affiliates get

Women smiling.

The opportunity to bring Mindbloom to your audience

A man resting on a couch.

A dedicated account manager to help you craft your campaigns

Books and pen and health instruments on a table.

Pre-approved copy and marketing materials

Measurable results

The largest-ever clinical study of ketamine therapy was recently published using data from 1,247 Mindbloom’s clients1.

Relief From Symptoms


of Mindbloom clients reported improvement in their depression and anxiety symptoms after 4 sessions

Relief From Suicidal Thoughts


of participants who reported suicidal ideation no longer reported any suicidal ideation after 4 sessions

Little to No Side Effects


of clients reported no side effects from their ketamine treatment with Mindbloom.

Symptom Remission is Possible


of clients experiencing depression and anxiety achieved remission (or virtually no symptoms) after 4 sessions.

Safety information
Important Safety Information

Mindbloom pairs individuals with licensed clinicians who are trained to diagnose and treat anxiety, depression, and other mental health conditions.  If one of the licensed clinicians, in their medical judgment, decides that ketamine is an appropriate treatment for an individual based on a clinical assessment, then the clinician may prescribe ketamine tablets that are compounded by pharmacies under Section 503A of the federal Food, Drug, and Cosmetic Act (FDCA).  Drugs compounded under Section 503A do not require FDA approval, and as such the FDA has not determined that the compounded ketamine prescribed is safe and effective for anxiety, depression, or other mental health conditions.  The use of ketamine for anxiety, depression, and many other mental health conditions, however, is supported by a body of scientific literature.  (Data on file).

Ketamine is a Schedule III controlled substance. Other drugs containing ketamine, which (unlike compounded drugs) are subject to FDA’s approval requirements, have been FDA-approved as an intravenous or intramuscular injection solution for induction and maintenance of general anesthesia. However, those drugs have not been FDA-approved for anxiety, depression, or other mental health conditions, and they have not been FDA-approved in tablet form. The approved label is available here.

Ketamine may cause serious side effects, including but not limited to risks of: sedation; dissociation; psychiatric events or worsening of psychiatric disorders, including problems in people with schizophrenia, severe personality disorders, or other serious mental disorders; dependence, abuse and misuse; anxiety; increases in blood pressure or heart rate; respiratory depression (breathing becomes slower and shallower and the lungs fail to exchange carbon dioxide and oxygen efficiently); lower urinary tract and bladder symptoms, including frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size; altered sense of time; dry mouth; elevated intraocular or intracranial pressure; loss of appetite; confusion; nausea/vomiting; blurred vision; and slurred speech.

The FDA has advised that at-home administration of compounded ketamine may present additional risks because a health care provider is not available onsite to monitor for adverse outcomes resulting from sedation and dissociation.

Mindbloom’s protocols and guidance have been designed to minimize the likelihood of experiencing these side effects or other adverse effects, and should be followed carefully. Ketamine should only be taken as directed by the treating clinician.

Do not proceed with ketamine treatment if any of the following apply to you:

  • Allergic to ketamine
  • Symptoms of psychosis or mania
  • Uncontrolled high blood pressure
  • CHF or other serious heart problem
  • Severe breathing problem
  • History of elevated intraocular or intracranial pressure
  • History of hyperthyroidism
  • Other serious medical illness
  • Pregnant, nursing, or trying to become pregnant

Ketamine has been found to cause moderate psychological dependency in some users.

  • In rare cases, frequent, heavy users have reported increased frequency of urination, urinary incontinence, pain urinating, passing blood in the urine, or reduced bladder size
  • Ketamine may worsen problems in people with schizophrenia, severe personality disorders, or other serious mental disorders
  • Users with a personal or family history of psychosis should be cautious using any psychoactive substance, including ketamine, and discuss potential risks with your clinician before proceeding with treatment
  • The dissociative effects of ketamine may increase patient vulnerability and the risk of accidents

To promote positive outcomes and ensure safety, follow these ketamine treatment guidelines:

  • Do not operate a vehicle (e.g., car, motorcycle, bicycle) or heavy machinery following treatment until you’ve had a full night of sleep
  • Refrain from taking benzodiazepines or stimulants for 24 hours prior to treatment
  • Continue to take antihypertensive medication as prescribed
  • Do not take ketamine while hungover or with alcoholic beverages
  • Refrain from consuming solid foods within 3 hours prior to treatment and liquids within 1 hour prior to treatment
  • Ketamine treatment should never be conducted without a peer treatment monitor physically present

A peer-reviewed study of Mindbloom’s client treatment outcomes was published in the Journal of Affective Disorders in 2022, titled At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. The FDA has not evaluated head-to-head trials comparing the safety of ketamine to other medications that are FDA-approved for the treatment of depression, anxiety, or other psychiatric disorders. Although some clients report that they had more success with ketamine than with FDA-approved therapies, these outcomes may not be typical.

For more information about the informed consent that clients review and sign prior to treatment, please visit

Exceptional outcomes

When compared to studies of traditional treatments and IV ketamine, at-home ketamine therapy produced a greater improvement in symptoms.

SSRI Antidepressants2
IV Ketamine3
Percent of Patients with >50% Reduction of Depression Symptoms
1 | 2 | 3 | 4
Learn More About Our Study

Real Mindbloom clients,
real stories


Mindbloom has been totally worth it. The ketamine treatments have decreased my anxiety significantly.

Wood Finisher

In just a few sessions, Mindbloom saved my life.

Retail Store Manager

I’ve built habits to support my wellbeing that will last the rest of my life.


Mindbloom helped build a foundation that I needed to keep me from spiraling and feeling lost.

Financial Advisor

I couldn’t feel happiness before ketamine treatment. I do now.

Nurse Practitioner

Ketamine therapy changed my life and I am beyond grateful.


For the first time in 20 years I have been able to phase out my anxiety medications.

Business Systems Analyst

I cannot believe how much better I felt in just a few short weeks. My quality of life has improved so much.

Healthcare Worker

Ketamine silenced the constant thoughts that have been torturing me for most of my life.

Business Owner

Mindbloom has helped me take back control of my life. I feel free.

Sales Engineer


How is safety monitoring done during Mindbloom’s ketamine assisted therapy program?

All clients must complete a comprehensive safety and screening process. If deemed eligible, clients meet directly with a licensed clinician to ensure Mindbloom and ketamine treatment are suitable for them. If approved, they are assigned a dedicated Guide for their program, and given a specific prescription/dosing protocol for their sessions. Before client sessions, the Guide and our programming help prepare the individual's mind and body. A Bloombox of essential material is also sent to clients to check their heart rate, blood pressure, and provide a safe and supportive experience. Throughout the program, a client can contact their Guide or their Clinician with any questions, and are required to have a Peer Treatment Monitor in the space with them for every dosing session they have.

Is Ketamine FDA approved?

Yes. Ketamine is FDA approved for certain medical uses, and is listed as a Schedule III compound by the DEA. Ketamine is primarily used as an anesthetic in medical settings, and is approved by the FDA as an off-label prescription treatment for depression, anxiety, chronic pain, PTSD, OCD, and substance dependencies at a clinician's discretion. Ketamine has been used in medical settings since the 1950’s, and remains on the World Health Organization’s List of Essential Medicines.

Is Ketamine addictive?

Ketamine has the potential for addiction and abuse when not following clinical protocols. It is a Schedule III controlled substance in the United States, recognizing that it has a moderate to low potential for physical and psychological dependence. Any use of ketamine that is not under the direction of an appropriate clinician can be considered misuse. This misuse can take the form of consuming ketamine without the direction of an appropriate clinician, using more ketamine than prescribed, or using ketamine more often than prescribed. When misused, ketamine can be addictive.

How long do the results last?

A single dosing session is followed by a 10-14 day ‘neuroplastic window’. Neurobiological outcomes such as increased neuroplasticity, heightened BDNF (brain-derived neurotrophic factor) levels and elevated baseline mood are seen during this ~2 week period. Ketamine treatment also helps to create favorable conditions for deeper emotional/psychological work, the positive results of which can help transform an individual for years to come.

How much do Mindbloom's new and continued programs cost?

Our 6-session Basics program for new clients costs $1,158. Clients who wish to repurchase Mindbloom have a few options. Our 6-session, standalone programs are $765 each, and our 18-session All Access program is $1,782. Clients referred to Mindbloom from partner providers receive 10% off the listed prices.

For clients prescribed Mindbloom by Partners, the cost for the Partner is $890 for the first 6 sessions, and $590 for subsequent packs of 6 sessions. Partners may set their own list price for the client.